What it is
KPV is a tripeptide made of three amino acids, lysine, proline, and valine, that makes up the last three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH), a hormone the body already uses to help control inflammation. Researchers isolated KPV because it appears to carry a large share of alpha-MSH's anti-inflammatory activity in a much smaller, more stable package, without the pigmentation effects the full hormone has on skin and hair.[1]
It's sold as a standalone research compound and is also a common component of blend products, most notably KLOW (GHK-Cu, BPC-157, TB-500, and KPV together), aimed at broader skin and tissue-repair research.
What researchers study it for
- Gut inflammation and colitis models Researchers have studied KPV in mouse models of inflammatory bowel disease, where treated animals showed earlier recovery, stronger weight regain, and fewer inflammatory cells in the colon compared to untreated animals.[2]
- The gut transporter that carries it in A 2008 study found that KPV is taken up by PepT1, a transporter that increases in the gut lining during inflammatory bowel disease, and that once inside the cell, KPV lowers two major inflammatory signaling pathways (NF-kB and MAPK). Oral KPV reduced colitis severity in the same study.[5]
- Inflammation research outside the gut In an animal model of peritonitis (inflammation of the abdominal lining), KPV reduced the buildup of immune cells at the inflamed site, and it did this through a different pathway than the one full-length alpha-MSH uses.[3]
- Skin and topical inflammation Because alpha-MSH's broader anti-inflammatory research spans irritant and allergic skin reactions, researchers have looked at KPV specifically as a candidate for inflammatory skin conditions, building on its role as alpha-MSH's active anti-inflammatory fragment.[1]
- Antimicrobial activity Laboratory studies have found that alpha-MSH and its KPV fragment can inhibit growth of common pathogens including Staphylococcus aureus and Candida albicans, across a wide range of concentrations, without reducing the immune system's own ability to kill these organisms.[4]
Research context
KPV's research base is built almost entirely on animal models and cell culture work, with the gut and colitis research being the deepest and most consistent thread. Multiple independent mouse studies, using different colitis models, have found the same basic pattern: KPV calms inflammation and speeds recovery, and it does this at least partly through a pathway (the PepT1 transporter) that is separate from the classic melanocortin receptors that full-length alpha-MSH uses.[2][5] That receptor-independent mechanism is also what shows up in the peritonitis and antimicrobial research, which suggests it isn't a fluke specific to one model.[3][4]
What's missing is human trial data. As of this writing, there are no published human randomized controlled trials on KPV specifically, so everything above should be read as preclinical: real, repeated, mechanistically coherent findings in cells and animals, not a treatment that's been tested in people. Researchers interested in KPV are, in effect, working from the same evidence base that supports alpha-MSH's broader anti-inflammatory reputation, applied to its most studied active fragment.
Typical research parameters
| Parameter | Typical range |
|---|---|
| Common vial sizes | 5 mg, 10 mg; also included as a component in blend products such as KLOW |
| Supplied as | Lyophilized (freeze-dried) powder |
| Storage | Lyophilized: refrigerated at 2 to 8°C, protected from light; reconstituted solution: refrigerated, use within a few weeks |
| Stability | Lyophilized powder is stable for extended periods under proper cold storage; reconstituted solution is less stable and should be used promptly |
| Administration studied | Oral and injected routes in animal models; in vitro cell culture (majority of published mechanism research) |
| Purity to look for | ≥98% by HPLC; third-party certificate of analysis recommended |
References
- [1] Luger TA, Brzoska T. alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Annals of the rheumatic diseases. 2007;66 Suppl 3. PubMed ↗
- [2] Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory bowel diseases. 2008;14(3). PubMed ↗
- [3] Getting SJ, et al. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. Journal of pharmacology and experimental therapeutics. 2003;306(2). PubMed ↗
- [4] Cutuli M, Cristiani S, Lipton JM, Catania A. Antimicrobial effects of alpha-MSH peptides. Journal of leukocyte biology. 2000;67(2). PubMed ↗
- [5] Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1). PubMed ↗